In this regard, it must be noted that the original FDA approval for the treatment of melanoma required a PD-L1 positivity of ≥ 1% using the PD-L1 pharmDx assay (although this has since been withdrawn as a requirement for treatment)63, suggesting that our melanoma cells could respond to BMS-202. Here, CD274 is linked to melanoma.